India opens seven anti-dumping investigations against Chinese goods in a single day, spanning antibiotics, tyre resins, lift rails and polyurethane chemistry, as the bilateral deficit tops 112 billion dollars
NEW DELHI, September 30, 2026
India’s Directorate General of Trade Remedies issued seven separate notifications dated September 29 initiating anti-dumping investigations into imports originating in China, a burst of trade defence activity that touches pharmaceutical active ingredients, rubber chemistry, building components and foam feedstocks in one stroke.
The products under investigation are para-tert-octyl phenol formaldehyde tackifier resin, used in tyre and rubber manufacturing; penicillin G and its salts; 6-amino penicillanic acid, a core antibiotic intermediate; T-shaped solid guide rails for elevators and lifts; amoxycillin trihydrate; montelukast sodium, a respiratory pharmaceutical raw material; and copolymer polyol, an input to flexible foam used in mattresses and upholstery.
Each investigation was initiated on the application of domestic Indian manufacturers alleging that dumped Chinese imports are causing material injury to their operations. Under Indian practice the DGTR, which sits within the Ministry of Commerce and Industry, conducts the investigation and makes a recommendation. The Department of Revenue in the Ministry of Finance takes the final decision on whether duties are imposed and at what level.
The simultaneity is the story. Seven initiations against a single origin on a single day is not an ordinary week’s output for any trade remedies authority, and it lands in a bilateral relationship where the commercial imbalance has reached a scale that Indian policymakers describe in structural rather than cyclical terms.
The number behind the notifications
India’s goods trade deficit with China reached 112.6 billion dollars in the 2025-26 fiscal year, the highest on record, up from 99.2 billion dollars the previous year. Indian exports to China rose 36.66 percent to 19.47 billion dollars, a strong percentage gain from a small base. Indian imports from China rose 16 percent to 131.63 billion dollars.
The asymmetry in those two figures explains the policy posture. Indian exports grew faster in percentage terms, but the absolute gap widened by more than 13 billion dollars in a single year because the import base is nearly seven times the export base. At current growth rates the deficit continues to widen even in years when Indian exports outperform.
The composition of Indian imports from China compounds the political salience. A substantial share sits in intermediate goods and chemical and pharmaceutical inputs, categories where India has declared strategic self-reliance objectives. Penicillin G and 6-amino penicillanic acid are the clearest example. India is one of the world’s largest formulators and exporters of finished antibiotic dosage forms, yet it has depended heavily on imported Chinese fermentation-derived intermediates for decades, having largely exited domestic fermentation capacity in the 1990s and 2000s when Chinese producers undercut Indian plants.
Successive Indian governments have tried to rebuild that capacity, most visibly through production-linked incentive schemes covering key starting materials and intermediates. Those schemes have produced new Indian fermentation plants for penicillin G. Those plants now need a price environment in which they can operate, which is precisely the case an anti-dumping petitioner makes.
How the instrument works and what it does not do
An anti-dumping investigation is a price and injury inquiry, not a trade policy judgement. The authority must find that the export price to India is below normal value in the exporting market, that the domestic industry is suffering material injury, and that there is a causal link between the two. If all three are established, duties are set at a level sufficient to remove the injury, which in Indian practice is often the lesser of the dumping margin and the injury margin.
Investigations of this kind typically run twelve to eighteen months from initiation to final determination, with the possibility of provisional duties considerably earlier if the authority makes a preliminary affirmative finding. Importers should therefore plan on the basis that provisional duties on some or all of these seven products could appear within roughly six months, and that any duties imposed will apply retrospectively to the date of the provisional measure in certain circumstances.
What the instrument does not do is set a ceiling on imports. Anti-dumping duties raise the landed price of the dumped product. They do not restrict volume, and they do not apply to imports from other origins. The predictable consequence, well documented across dozens of Indian cases, is trade diversion toward third-country suppliers, followed in some cases by circumvention investigations and by anti-dumping petitions against the new origins.
That pattern is already visible elsewhere in India’s docket. On September 23 the DGTR recommended a five-year extension of anti-dumping duties on aluminium foil of 80 microns and below imported from China, Thailand, Malaysia and Indonesia, following a sunset review sought by six domestic producers including Hindalco Industries, LSKB Aluminium Foils, Raviraj Foils, Shree Venkateshwara Electrocast, Shyam Sel and Power and SRF Altech. Existing duties on that product range from 93.53 dollars to 976.99 dollars per tonne. The sunset review record noted that despite duties in force there remain significant imports, particularly from Thailand, and concluded that Chinese exporters are highly export oriented and likely to increase shipments if duties lapse.
The reasoning in that finding is the clearest available statement of how Indian authorities are thinking. The concern is not only the price at which a given consignment arrives, but the structural export orientation of the producing industry and the capacity it can redirect.
Stakeholder positions
Domestic Indian producers in the affected categories have been the most vocal constituency and are the direct applicants in each case. Their argument, consistent across the pharmaceutical intermediates and the specialty chemicals, is that Indian capacity built with public support cannot reach scale while imported product is available below cost.
Indian formulators and downstream users take the opposite view. For a company making finished antibiotic formulations for domestic sale and export, penicillin G and 6-amino penicillanic acid are raw materials, and a duty on them is a cost increase that either compresses margin or raises the price of medicines. India’s pharmaceutical export industry competes globally on cost, and its competitiveness in regulated and semi-regulated markets depends on input economics. Duties on upstream intermediates redistribute value within the Indian pharmaceutical chain from formulators toward fermentation producers. Whether that is a net gain for the Indian economy depends on how one weighs supply security against consumer and export prices, and reasonable people in Indian policy circles disagree.
The elevator guide rail case has a different character. That product serves construction and infrastructure, and duties feed into the cost of vertical transport equipment in a country undertaking one of the largest urban construction programmes in the world. The copolymer polyol case touches mattress and furniture manufacturing, a labour-intensive sector where Indian producers compete with imported finished goods as well as imported inputs.
Beijing’s standing position on Indian trade remedies has been that they are used excessively and that India is among the most frequent users of anti-dumping measures globally. That characterisation is factually defensible on case counts. India has been one of the top initiators of anti-dumping proceedings for most of the past two decades. Indian officials respond that case frequency reflects the volume and pricing behaviour of imports rather than any predisposition of the authority.
Economic impact
The direct value at stake in these seven cases is modest relative to a 131 billion dollar import bill. None of the seven products is a top-line import category. The significance is compositional rather than aggregate.
Pharmaceutical intermediates are the most consequential. If duties are imposed on penicillin G, 6-amino penicillanic acid and amoxycillin trihydrate, the effect will be felt in the cost base of Indian antibiotic production, which supplies a large share of the developing world’s essential medicines. Buyers of Indian finished antibiotics in Africa, Southeast Asia and Latin America would see input cost pressure transmitted through to prices, with a lag, unless Indian fermentation capacity scales fast enough to substitute at competitive cost.
Montelukast sodium follows the same logic in the respiratory category. Copolymer polyol and the tackifier resin feed into manufacturing sectors where Indian producers compete with imports of the finished article, so duties on the input without corresponding protection on the output can compress domestic converters between a higher input cost and unchanged finished-goods competition. That inversion is a familiar problem in tariff design and is the standard argument downstream users bring to Indian trade remedy proceedings.
The broader macroeconomic effect is small. The signalling effect is not. Seven initiations in a day tells every exporter to India, and every importer in India, that the trade remedies machinery is running at high throughput and that the probability of a given Chinese-origin product line attracting a case has risen.
Implications for importers, exporters and supply chains
Companies importing any of the seven products into India should assume a meaningful probability of provisional duties within six to nine months and should begin qualifying alternative origins now rather than after a preliminary determination. Qualification timelines for pharmaceutical intermediates are long, involving regulatory filings and change control, so a wait-and-see posture on penicillin G or 6-amino penicillanic acid risks being caught with no qualified alternative at the moment a duty lands.
Exporters in China facing these cases should participate. Non-participation in an Indian anti-dumping proceeding typically results in a residual duty rate set at the highest level found for any exporter, applied to all non-cooperating parties. Exporters who file questionnaire responses and accept verification frequently secure company-specific rates materially below the residual rate. The cost of participation is meaningful but almost always lower than the cost of a residual rate.
Third-country producers in Southeast Asia, Korea, Japan and Europe should read these initiations as a demand signal. Indian buyers will be looking for alternative sources, and the aluminium foil sunset review shows how quickly volume shifts to Thailand, Malaysia and Indonesia when Chinese product carries duty. Those producers should also understand the second half of that lesson: a successful capture of diverted volume frequently attracts its own anti-dumping petition within two to four years.
For global supply chain planners, the structural point is that India is now running a trade remedies programme of a scale and tempo comparable to the largest users of these instruments. Any sourcing strategy that treats India as a low-friction import market for Chinese-origin intermediates is working from an outdated premise. Pricing models for delivered cost into India should carry an explicit trade-remedy risk premium for product categories where domestic Indian capacity exists or is being built with policy support, because those are precisely the categories where a petition is most likely to succeed.
Product by product: where the pressure is greatest
The seven cases are not equivalent in economic weight or in the difficulty of the substitution problem they create, and buyers should triage them accordingly.
Penicillin G and 6-amino penicillanic acid. These are the strategic files. Penicillin G is produced by fermentation, a capital-intensive process with long commissioning timelines and significant environmental permitting requirements. 6-amino penicillanic acid is derived from it. Together they sit upstream of a large fraction of the world’s beta-lactam antibiotic supply. China holds a dominant global position in both. India’s attempt to rebuild domestic fermentation has produced plants, but ramping a fermentation facility to consistent yield and cost parity takes years. Duties imposed before that ramp completes raise Indian formulators’ costs without a domestic alternative available at volume, which is the classic timing risk in infant-industry protection.
Amoxycillin trihydrate. A step further downstream, and a product where Indian capacity is better established. The substitution problem here is less acute, though amoxycillin economics depend on 6-amino penicillanic acid pricing, so duties on both products compound in the same cost stack.
Montelukast sodium. A high-volume respiratory active ingredient with several qualified global sources outside China, including domestic Indian producers. This is the case where alternative sourcing is most readily available, and where duties are least likely to create a supply problem.
Para-tert-octyl phenol formaldehyde tackifier resin. A specialty chemical used in tyre compounding. Indian tyre manufacturers are large, sophisticated buyers with global procurement, and the alternative sources are European, Japanese and Korean producers at higher cost. Duties here transmit into tyre manufacturing costs in a market where Indian tyre makers compete with imported tyres, some of which already carry their own trade remedies.
T-shaped elevator guide rails. A heavy, low-value-density product where freight cost is a meaningful share of landed price. That freight sensitivity means regional supply has a natural advantage and duties could plausibly shift sourcing to domestic Indian rolling capacity relatively quickly.
Copolymer polyol. A polyurethane foam intermediate. Regional alternatives exist in Southeast Asia and the Middle East. The affected Indian downstream sector, mattresses and furniture, is fragmented and price-sensitive, and a cost increase is likely to be passed to consumers rather than absorbed.
Procedural timeline importers should diarise
Indian anti-dumping practice follows a reasonably predictable sequence, and importers can plan against it.
Following initiation, interested parties normally have around thirty to forty days to file questionnaire responses and register as interested parties. Failure to register within the window forfeits standing to comment on the record, a procedural trap that catches importers who assume the exporter will defend their interests. Importer and user interests are not identical to exporter interests, and the user-interest submission is the only vehicle for arguing that duties would damage downstream Indian industry.
A preliminary determination, if made, typically arrives within six to nine months of initiation and may be accompanied by provisional duties secured by bond or cash deposit. A final determination and recommendation ordinarily follows within twelve to eighteen months of initiation, with the Department of Revenue then deciding whether to notify duties. Duties, when notified, normally run five years subject to sunset review, as the aluminium foil case illustrates.
The practical implication for a company importing any of the seven products is that the decision point is now, not at the preliminary determination. Qualification of an alternative supplier for a pharmaceutical intermediate can take longer than the entire investigation.
What this says about the direction of Indian trade policy
India concluded a free trade agreement with the European Union earlier this year and has been negotiating tariff terms with the United States. Those tracks point toward liberalisation with partners India regards as complementary. The anti-dumping docket points in the opposite direction with respect to China specifically.
There is no contradiction in that, and it is worth stating plainly because the two facts are often presented as inconsistent. India’s revealed strategy is preferential opening toward economies whose export profile complements its own, combined with contingent protection against the single origin that competes directly across the widest range of Indian manufacturing. Trade remedies are the legally available instrument for the second objective, since India cannot simply raise applied tariffs on Chinese goods without breaching bound rates or most favoured nation obligations.
Exporters and importers should expect the tempo to be maintained. The policy logic behind these seven initiations has not changed and the deficit figure that motivates it is still widening.
The wider frame
India’s posture sits within a broader global pattern in which the largest economies are simultaneously raising the cost of Chinese-origin goods through different instruments. The European Union has been imposing definitive anti-dumping duties across an expanding list of Chinese product lines and is weighing a broader trade defence instrument. Mexico raised tariffs on non-FTA Asian origins. Japan and Korea have brought steel cases. Each measure operates independently, and each redirects a quantum of Chinese export capacity toward the markets that have not yet acted.
That dynamic creates a coordination problem with no obvious solution under existing rules. Every jurisdiction that acts makes the case for action stronger in every jurisdiction that has not. India’s seven initiations in a single day are both a response to that dynamic and a contribution to it.
The Finance Ministry’s decisions on these cases, expected across 2027, will show how far New Delhi is prepared to take the import-substitution logic when the cost falls on its own export-oriented pharmaceutical sector. That is the genuinely difficult trade-off inside these files, and it will not be resolved by the dumping margin calculation alone.